Cover Image
市場調查報告書

間質性膀胱炎 (膀胱疼痛症候群) :開發中產品分析

Interstitial Cystitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213127
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
間質性膀胱炎 (膀胱疼痛症候群) :開發中產品分析 Interstitial Cystitis - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 82 Pages
簡介

間質性膀胱炎,是同時也稱為膀胱疼痛症候群的慢性疾病,包含膀胱壓、膀胱痛、骨盆痛等,輕度不舒服到劇痛。症狀有膀胱容量低,性交痛,慢性骨盆痛,頻尿,尿急感等。危險因素為年齡、性別、慢性疼痛性障礙(大腸躁鬱症、纖維肌痛症等)。治療包含非類固醇消炎劑、抗憂鬱藥、抗組織胺藥等。

本報告提供間質性膀胱炎 (膀胱疼痛症候群) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

間質性膀胱炎 (膀胱疼痛症候群)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

間質性膀胱炎 (膀胱疼痛症候群):企業開發中的治療藥

間質性膀胱炎 (膀胱疼痛症候群):大學/機關研究中的治療藥

間質性膀胱炎 (膀胱疼痛症候群):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

間質性膀胱炎 (膀胱疼痛症候群):企業開發中的產品

間質性膀胱炎 (膀胱疼痛症候群):大學/機關研究中的產品

間質性膀胱炎 (膀胱疼痛症候群)的治療藥的開發企業

  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Aquinox Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Kytogenics Pharmaceuticals, Inc.
  • Lipella Pharmaceuticals, Inc.
  • MediPost Co., Ltd.
  • Qu Biologics Inc.
  • UCB S.A.
  • Urigen Pharmaceuticals, Inc.
  • UroGen Pharmaceuticals, Ltd.

間質性膀胱炎 (膀胱疼痛症候群):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

間質性膀胱炎 (膀胱疼痛症候群):最近的開發平台趨勢

間質性膀胱炎 (膀胱疼痛症候群):暫停中的計劃

間質性膀胱炎 (膀胱疼痛症候群):開發中止的產品

間質性膀胱炎 (膀胱疼痛症候群):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9184IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H1 2017, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 6 and 1 respectively.

Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interstitial Cystitis (Painful Bladder Syndrome) - Overview
    • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Aquinox Pharmaceuticals Inc
    • Astellas Pharma Inc
    • BELLUS Health Inc
    • Kytogenics Pharmaceuticals Inc
    • Lipella Pharmaceuticals Inc
    • Merck & Co Inc
    • UCB SA
    • Urigen Pharmaceuticals Inc
    • Xigen SA
  • Interstitial Cystitis (Painful Bladder Syndrome) - Drug Profiles
    • (heparin + lidocaine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AF-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQX-1125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6294 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimapitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-16357 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mesalamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URG-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
  • Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
      • Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
      • May 25, 2016: Aquinox Announces Executive Appointments
      • May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
      • May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego
      • Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
      • Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
      • Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
      • Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
      • Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
      • Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
      • May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
      • Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by BELLUS Health Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Merck & Co Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB SA, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Xigen SA, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top